

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Surender KHARBANDA

Donald W. KUFE

Serial No.: 10/577,003

Filed: December 13, 2006

For: MODULATION OF INTERACTION OF
MUC1 WITH MUC1 LIGANDS

Group Art Unit: 1643

Examiner: Anne Gussow

Atty. Dkt. No.: GENU:005US

Confirmation No.: 1914

CERTIFICATE OF ELECTRONIC TRANSMISSION	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
March 7, 2011	
Date	Steven L. Highlander

INVENTOR'S DECLARATION UNDER 37 C.F.R. §1.132

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

I, Surender Kharbanda, do declare that:

1. I am the Surender Kharbanda named as an inventor on the above-captioned application.
2. My *curriculum vitae* is attached hereto as evidence of my expertise.

3. **Generation of MUC1-C-ED-Fc chimeric proteins [Glycosylated (GO-101) and Unglycosylated (GO-102)].** Human MUC1-C-ED (Figure 1) was fused with the PCR-amplified mouse or human IgG Fc fragment and cloned into the pCR3.1 vector between NheI and XbaI sites. The pCR3.1 mFc-MUC1-C-ED or pCR3.1 hFc-MUC1-C-ED plasmids were stably transfected into the Chinese Hamster Ovarian (CHO) cell line CHO-K1. Separately, these plasmids were also transfected into mutant Lec1-CHO cells, which lack GlcNAc glycosyl transferase so that N-linked carbohydrates are blocked at the Man5-GlcNAc2-Asn intermediate. This cell line is used to produce the unglycosylated mFc-MUC1-C-ED and hFc-MUC1-C-ED chimeric proteins. These stable cell lines were grown in BD cell monoclonal antibody production chambers (Cell line 1000) in serum free media. Secreted proteins in the supernatant were passed through protein-A column, washed extensively and eluted with 0.1 M Citric acid, pH 3.0. The eluted proteins were concentrated and run on SDS-PAGE gels to confirm size and purity. The human Fc-MUC1-C-ED glycosylated protein is designated as GO-101 and unglycosylated protein is designated as GO-102.




Figure. 1. Schematic representation of the transmembrane MUC1-C subunit and amino acid sequence of the extracellular domain (MUC1-ED).

Based on the data from initial *in vitro* cell proliferation experiments, further in-depth experiments were performed with GO-101, as discussed below.

4. **Inhibition of estrogen-dependent human breast carcinoma cell proliferation by GO-101 *in vitro*.** Human ZR-75-1 breast carcinoma cells (10,000 cells/well) were plated into 24-well tissue culture plates and grown for 24 h at 37°C. Cells were then independently treated each day with different concentrations (50 nM, 250 nM and 500 nM) of GO-101. All treatment points were set-up in triplicates. As a negative control, cells were also treated with same concentrations of purified hFc protein. Plates will be subsequently incubated for an additional 3 days. After the end of the incubation period, cell proliferation was determined using trypan blue exclusion method. The percent proliferation of ZR-75-1 cells is shown in Figure 2.




Figure 2: ZR-75-1 cells were treated with the indicated concentrations of GO-101 each day for 3 days. The cell proliferation was measured by trypan blue exclusion method. The percent proliferation is shown to that compared with control.

Similar results were obtained when another estrogen-dependent breast carcinoma cell line MCF-7 was treated with different concentrations of GO-101 (Figure 3).




Figure 3: MCF-7 cells were treated with the indicated concentrations of GO-101 each day for 3 days. The cell proliferation was measured by trypan blue exclusion method. The percent proliferation is shown to that normalized with control.

5. Inhibition of non-small cell lung carcinoma cell proliferation by GO-101 *in vitro*.

Human H1975 non-small cell lung carcinoma cells (10,000 cells/well) were plated into 24-well tissue culture plates and grown for 24 h at 37°C. Cells were then independently treated each day with different concentrations (50 nM, 500 nM and 5000 nM) of GO-101 for three days. All treatment points were set-up in triplicates. As a negative control, cells were also treated with same concentrations of purified hFc protein. After 3 days of treatment, cell proliferation was determined using trypan blue exclusion method. The percent proliferation of H1975 cells is shown in Figure 4.




Figure 4: *H-1975 non-small cell lung carcinoma cells were treated with the indicated concentrations of GO-101 each day for 3 days. The cell proliferation was measured by trypan blue exclusion method. The percent proliferation is shown to that compared with control.*

6. **Dose response study of GO-101 in hormone-dependent ZR-75-1 human breast carcinoma tumor xenograft model.** To study the effects of multiple doses of GO-101 on ZR-75-1 human breast carcinoma xenograft in mice, we have performed a pilot study (2 doses only with 5 mice in each group) using a batch of 25 mgs of GO-101.

About 9-10 week old female mice (on the day of treatment) (CRL: NU-Foxn1nu) were obtained from Charles River Labs. The mice were fed irradiated Rodent Diet 5053 and water ad libitum. All the treatments, body weight determinations and tumor measurements were carried out in the bubble environment. Test animals were implanted subcutaneously, high in the right axilla, on Day 0 with 5×10^6 cells/animal (0.2 ml) using a 27 gauge needle and syringe.

ZR-75-1 cells were obtained from ATCC and expanded using RPMI 1640 media supplemented with 10% Fetal Bovine Serum (heat inactivated), 1% penicillin-streptomycin-

glutamine, 1% HEPES, 1% Na-Pyruvate and 1% glucose in 5 % CO₂ atmosphere at 37°C. When expansion was complete, the cells were trypsinized and pooled for implantation. The ZR-75-1 (passage 7) cell suspension was counted using trypan blue exclusion. A 2×10^7 cells/ml suspension was prepared in serum free RPMI 1640 with 50% Matrigel. The pre-injection viability was 95.8%

ZR-75-1 human breast carcinoma is an estrogen-dependent tumor model, and all of the mice were implanted with 17-b estradiol pellets (0.36 mg/pellet, 60 day release, Innovative Research of America). The pellets were implanted subcutaneously on the back of the neck with a 10-gauge trocar needle prior to tumor implant. Blood levels of 17-b estradiol were not monitored during the experiment.

Treatments began on Day 17, when the mean estimated tumor mass for all groups in the experiment was 136 mg (range of group means, 129-144). All animals weighed ≥ 23.8 g at the initiation of therapy. Mean group body weights at first treatment were well-matched (range 25.4-28 g). All animals dosed with either the vehicle or different concentrations of GO-101 were injected with a fixed volume of 100 μ l as shown in Table 1.

All mice were observed for clinical signs at least once daily. Mice with tumors in excess of ~1g or with ulcerated tumors were euthanized. All procedures were carried out in this experiment were conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH) and with the approval of Discovery and Imaging Services, Ann Arbor's (DIS-AA) Animal Care and Use Committee. DIS-AA is an AAALAC accredited facility. Body weights and tumor measurements were recorded twice weekly. Tumor burden (mg) was estimated from caliper measurements by the formula for the volume of a prolate ellipsoid assuming unit density as:

Tumor burden (mg) = $(L \times W^2)/2$, where L and W are the respective orthogonal tumor length and width measurements (mm)

Table 1

Groups	Compound	# of Mice	Route	Schedule	Dose (mg/kg)
1	Vehicle	5	ip	QD x 21	100 ml
2	GO-101	5	ip	QD x 21	1 mg/kg
3	GO-101	5	ip	Q3D x 7	10 mg/kg

The mean estimated tumor mass for all groups on day 1 of treatment in the experiment was 136 mg (range of group means, 129-144). A tumor burden of ~750 mg in the vehicle-treated group was chosen for evaluation of any sign of efficacy by tumor growth delay. The median vehicle tumor reached evaluation size on Day 30. Treatment of GO-101 at 1 mg/kg daily x 21 showed no sign of toxicity. Treatment with GO-101 twice weekly at 10 mg/kg was well-tolerated, produced no treatment-related mortality and maximum treatment-related weight losses of ~8%. Treatment of GO-101 at 1 mg/kg daily x 21 failed to produce anti-cancer activity ($p>0.05$) (Figure 5). However, treatment with GO-101 at 10 mg/kg twice weekly (only 6 doses for the entire study) produced some tumor growth inhibition starting at Day 16. These findings suggest a trend of increasing anti-cancer activity dependent on dose. Taken together, our results demonstrate that doses of GO-101 such as 5 mg/kg daily x 21 or 10 mg/kg every other day x 21 will be significantly effective in tumor growth inhibition.





Figure 5: ZR-75-1 human breast carcinoma bearing nu/nu mice were dosed with either vehicle (squares), 1 mg/kg GO-101 i.p daily x 21 days (triangles) or 10 mg/kg GO-101 i.p. twice weekly for 3 weeks. Tumors were measured twice a week.

7. From the preceding data, it is clear that GO-101 is able to effectively inhibit cancer cells (*in vitro*) and treat cancer (*in vivo*) directly without first generating antibodies which then effect the inhibition and treatment. This result is neither disclosed nor suggested by the references upon which the examiner is relying.

8. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

3-3-2011

Date



Surender Kharbanda, Ph.D.

CURRICULUM VITAE

Harvard Format

Date Prepared: February 11, 2011

Name: Surender M. Kharbanda, Ph.D

Present Positions: Scientific Founder
& Chief Scientific Officer
Genus Oncology LLC
BU BioSquare # 131
650 Albany Street
Boston, MA 02118
Tel: (617) 638-0360
skharbanda@genusoncology.com

Principle Research Scientist
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA 02115
Tel: 617-632-6281
Fax: 617-632-2934
e-mail:
surender.kharbanda1@dfci.harvard.edu

Founder & Director
Linus Pharmaceuticals Inc.,
Miami, Florida
e-mail: skharbanda@linuspharma.com

Previous Academic Position: Assistant Professor
Department of Adult Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA 02115

Previous Industry Position: Vice President, Head of Research,
Research & Development
ILEX Oncology Inc.,
Boston, Massachusetts 02215

Other Professional Affiliations/Positions:

2009-	Member	Vanas Oncology LLC
	Scientific Advisory Board	Cambridge, MA

2009-	Chairman Scientific Advisory Board	NanoMol Therapeutics Pvt. Ltd., New Delhi, India
2010-	Member Scientific Advisory Board	MinnAmrita Therapeutics LLC Minneapolis, MN

Education:

1977	Bachelor of Science Chemistry (with Honors), University of New Delhi, New Delhi, India. First class first in University
1979	Master of Science, Organic Chemistry, University of New Delhi, New Delhi, India. 'A' Grade and First in University
1985	Ph.D., Cell Biology/Biochemistry, All India Institute of Medical Sciences, New Delhi, India. Thesis entitled: "Role of synthetic progestins and anti-progestins in steroidogenesis in human ovary"

Academic/Industry Appointments:

1979-1980	Junior Research Fellow, All India Institute of Medical Sciences, Indian Council of Medical New Delhi, India
1980-1985	Graduate Student, Ph.D Program. All India Institute of Medical Sciences, New Delhi, India
1985-1986	Senior Research Officer, All India Institute of Medical Sciences, New Delhi, India
1986-1989	Research Fellow in Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts

1989-1991	Research Associate, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts
1991-1993	Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute Boston, Massachusetts
1993-2000	Assistant Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts
2000-2005	Vice President, Head of Research Research & Development, ILEX Oncology Inc., Boston, Massachusetts 02215
2005-	Principle Research Scientist Department of Medical Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, MA 02115
2007-	Founder & Chief Scientific Officer Genus Oncology LLC BU Bio-Square 670 Albany Street, Suite # 116 Boston, MA 02118
2009-	Founder & Director Linus Pharmaceuticals Inc., Miami, Florida

Key Accomplishments in Pharmaceutical Industry

ILEX Oncology Inc.,

I was involved in over-seeing Ilex Boston Research Facility and Ilex Geneva Research Facility with a total scientific force of 42.

Effective leadership requires a unique blend of tools, skills and personality characteristics. I provided a leadership role to establish the Ilex Oncology Research Facility in Boston as a center of excellence for oncology research.

- Was part of the team that developed three oncology drugs:

Clofarabine/Clolar (Small Molecule)	Approved	Pediatrics ALL/AML
NM-3/Isocoumarin (Small molecule)	Phase I/II	Solid Tumors
Tumstatin (Biologic)	Late Stage Preclinical	Solid Tumors
- Provided a leadership role in independently directing all the scientific programs of ILEX Oncology Research Facility.
- Built an effective, hard working, stabilized and focused scientific workforce by hiring top-notch scientists from excellent academic [Harvard, MIT] and pharmaceutical organizations.
- Enhanced the image and value of ILEX Oncology Research through multiple publications and presentations.
- In-licensed Oncology Programs to ILEX through contacts and collaborators from the highly recognized academic centers.
- Successfully initiated and managed research collaborations outside ILEX Oncology that resulted in multiple scientific publications with ILEX compounds.

- Provided leadership support to all of ILEX Oncology's NPO's, in-licensing and out-licensing
- Fifteen full-length manuscripts were published from Ilex Oncology in collaboration with multiple academic centers. Twenty-seven abstracts were presented in various National and International scientific meetings from Ilex Oncology.

Genus Oncology LLC

Developed 3 NCE's from basic research program in less than three years:

GO-203-2C (Biologic)	Filing IND	Phase I (1 st patient, Dec 2010)
GO-101 (Biologic)	Late-stage Preclinical	
GO-401 (Small Molecule)	Lead Optimization	

Research Interests:

Apoptosis/Cell Death

Angiogenesis

Signal Transduction [Kinases, Phosphatases]

Growth Factor Receptors [erbB2, EGFR]; MUC1.

The cellular response to stress includes cell cycle arrest, activation of DNA repair and induction of apoptosis. However, the molecular signaling events that determine cell fate, that is survival or apoptosis, are largely unknown. My research is focused on elucidation of the signaling mechanisms that regulate the response to diverse classes of stress. Specifically, my work is

directed at determining how stress is converted into intracellular signals that control cell behavior.

My previous work has shown that the c-Abl protein tyrosine kinase is activated by diverse types of DNA damage. Moreover, my recent findings demonstrate that the DNA-dependent protein kinase (DNA-PK) and the ataxia telangiectasia mutated (ATM) gene product, effectors in the DNA damage response, contribute to the induction of c-Abl activity. Since c-Abl is primarily activated by DNA strand breaks, one of my projects involves studies of the role of c-Abl in normal cellular processes, such as meiotic recombination, that are also associated with DNA-strand interruptions.

Apoptotic cell death is a critical feature of the regulated development of multicellular organisms. A major focus on the regulation of apoptosis has been the identification of new molecules that positively or negatively modulate cell survival. My previous work has shown that release of mitochondrial cytochrome c in cells exposed to diverse types of stress agents is an effector of the apoptotic response. Whereas cytochrome c release is inhibited by the anti-apoptotic protein Bcl-xL, another project involves mechanistic studies underlying cytochrome c-dependent activation of the caspase cascade and regulation of apoptosis. This aspect of my research includes work on identifying novel negative physiological regulators of cytochrome c-dependent apoptosis induced in response to genotoxic agents.

Heat-shock Proteins: Apoptosis is induced by release of mitochondrial cytochrome c and activation of the Apaf-1 (procaspase-9) (procaspase-3) cascade. My group has identified a set of proteins that function as negative regulators of this pathway. These proteins belong to the heat-shock family (Hsp90 and Hsp70) and inhibit cytochrome c-mediated activation of caspases. Their mechanisms of inhibition of cytochrome c-mediated apoptosis are different. We have demonstrated that Hsp90 inhibits cytochrome c-dependent oligomerization of Apaf-1 and thereby activation of procaspase-9. This aspect of my research includes work on defining the signals that regulate the interactions of Hsp90 and Apaf-1 in response to stress.

Angiogenesis, the formation of new blood vessels from existing vasculature, is a tightly regulated event and is essential in pathological conditions such as tumor growth and progression. Tumor angiogenesis involves several processes, including endothelial cell activation, proliferation, migration

and organization into tubes. The development of new combination therapies that increase the effectiveness of standard chemotherapeutic drugs is important. My other expertise of research includes work on identifying novel inhibitors of angiogenesis.

MUC1-C Receptor Oncoprotein: The MUC1 transforming protein is overexpressed by most human carcinomas. This transmembrane glycoprotein is aberrantly overexpressed in about 800,000 of the 1.3 million tumors diagnosed in the U.S. each year. MUC1 interacts with the ErbB and Wnt signaling pathways and induces transformation. Our recent studies demonstrate that MUC1 localizes to mitochondria and that MUC1 blocks activation of the intrinsic apoptotic pathway by genotoxic agents. Our results also demonstrate that MUC1 confers resistance to treatment in animal tumor models. Taken together, our recent findings indicate that overexpression of MUC1 in human tumors could be of importance to the effectiveness of anticancer therapy.

Previous Scientific Consultancies:

2008-2009	Consultant	Celceutix Inc., Beverly, MA
2007-2008	Consultant	SemaCo Pharmaceuticals Inc., Boston, MA 02118
2006-2008	Consultant	Translational Genomics Institute TD2, Phoenix, Arizona
1998-2000	Consultant	Novartis Pharmaceuticals Inc., Summit, New Jersey
1998-2000	Consultant	Asahi Chemical Inc., Mount Fuji, Japan.
1992-1994	Consultant	New England Nuclear, Boston, Massachusetts

Professional Society Involvement:

1992-	Member	American Association of Cancer Research (AACR)
1995-	Member	American Association for the Advancement of Science (AAAS)
2000-	Member	Boston Cell Death Club, Harvard Medical School, Boston, MA
2002-	Faculty	Faculty of 1000 [F1000] London, England

Editorial Boards:

2001	Guest Editor	The Journal "APOPTOSIS", special issue on Reviews, Apoptosis for Clinicians, Feb- April, Volume 6, Issue 1 and 2, 2001
2002-		Member, Editorial Board of the Scientific Journal "Apoptosis"
2002-		Editorial Board Member, Faculty of 1000[F1000], London, England

Reviewer of Scientific Journals:

1997-	Reviewer	Journal of Biological Chemistry [JBC]
1998-	Reviewer	Molecular & Cellular Biology [MCB]
1997-	Reviewer	Oncogene
1996-	Reviewer	Blood
1995-	Reviewer	Cancer Research
1996-	Reviewer	Radiation Research

1996-	Reviewer	CG&D
1997-	Reviewer	Leukemia Research
1997-	Reviewer	Biochemical Pharmacology
1997-	Reviewer	Leukemia
1998-	Reviewer	BBA
1999-	Reviewer	Clinical Cancer Research
2000-	Reviewer	Cancer Letters

Scientific Grants Review Board:

1995-2000	Reviewer	The Israel Science Foundation, Administered by the Israel Academy of Science and Humanities
1996-2000	Reviewer	The Children's Hosp. of Winnipeg Research Foundation Inc., Winnipeg, Manitoba, Canada
2001-2002	Reviewer	Austrian Science Fund, Weyringergasse 35, A-1040 Wien, Austria
2001-2005	Reviewer	The Wellcome Trust, 183 Euston Road, London, UK

Invited Speaker:

April, 1996	Robert Wood Johnson Cancer Center, New Jersey
Aug, 1996	Department of Radiation Biology, University of Chicago, Chicago, Illinois
Sept, 1996	Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada

May, 1997	Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Oct, 1997	National Institute of Immunology, New Delhi, India
Nov, 1997	International Center for Genetics and Biotechnology, New Delhi, India
Nov, 1997	Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, India
Nov, 1997	All India Institute of Medical Sciences (AIIMS), New Delhi, India
Dec, 1997	Department of Biochemistry, University of New Delhi, New Delhi, India
Jan, 1998	Allegheny University Hospitals, Philadelphia, Pennsylvania
April, 1999	Dana-Farber Cancer Institute-Novartis Pharmaceuticals Joint Annual Retreat on Apoptosis, Beaune, France
March, 2000	Department of Radiation Oncology, University of Chicago, Chicago, IL
April, 2000	Dana-Farber Cancer Institute-Novartis Pharmaceuticals Joint Annual Retreat on Apoptosis, Delaware, Wellmington, USA
August, 2000	Department of Cell Biology, Lovelace Respiratory Res. Institute, Alberquerque, NM
Oct, 2000	Department of Medicine, University of Zurich, Zurich, Switzerland
Nov, 2000	Boston Cell Death Club, Boston, MA
July, 2001	Department of Radiation Oncology, University of Chicago, Chicago, IL

Feb, 2002	Signal Transduction Seminar series; Department of Experimental Therapeutics, U.T.M.D. Anderson Cancer Center, Houston, Texas.
April, 2002	World Drug Discovery Summit, Copenhagen, Denmark
January, 2003	Division of Cancer Pharmacology, Dana- Farber Cancer Institute, Harvard Medical School, Boston, MA
May, 2003	Department of Radiation Oncology, University of Chicago, Chicago, IL
April, 2004	Department of Neurobiology Boston University Medical Center Boston, MA
December, 2004	NDDR [New Drug Discovery Research] Ranbaxy Research Laboratories, Gurgaon, India
May, 2005	Division of Oncology Serono Biomedical Research Institute Rockland, MA
Feb, 2006	Department of Cardiology and Cardio- vascular Discovery University of California at Irvine [UCI] Irvine, CA
Nov, 2006	Department of Surgery University of Minnesota, Minneapolis, MN
March, 2007	Central Drug Research Institute [CDRI] Lucknow, India
March, 2007	Institute of Bioinformatics and Applied Biotechnology, Bangalore, India
April, 2008	Department of Medical Oncology, Jikei University, Tokyo, Japan

April, 2008	Division of Research & Development FUSO Pharmaceuticals Ltd., Osaka, Japan
July, 2009	Department of Chemistry, Indian Institute of Technology, New Delhi, India
July, 2009	Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, India

Bibliography

1. Band V, Kumar R, Kharbanda S, Band AH, Murugesan K, Farooq A. Production of prostacyclin by different cell types of the goat ovary. **Prostaglandins** 1985;30:323-334.
2. Band V, Kharbanda S, Murugesan K, Farooq A. Effect of forskolin and phosphodiesterase inhibition of prostacyclin-stimulated steroid production in goat ovarian cell types. **Prost Leuco Med** 1985;22:111-116.
3. Band V, Kharbanda S, Murugesan K, Farooq A. Prostacyclin and steroidogenesis in goat ovarian cell types in vitro. **Prostaglandins** 1986;31:507-524.
4. Kharbanda S, Band V, Murugesan K, Verma U, Bhargava VL, Farooq A. Synthetic antiprogestins stimulate human granulosa cell estradiol production in vitro. **Experimental and Clinical Endocrinology** 1987;89:174-80.
5. Band V, Kharbanda S, Murugesan K, Farooq A. Steroid production in vitro by granulosa, theca and corpus leuteum cells from goat ovary. **Biology of Reproduction** 1987;36:799-809.
6. Kharbanda S, Sherman ML, Spriggs DR, Kufe DW. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation. **Cancer Research** 1988;48:5965-5968.
7. Kharbanda S, Miyazaki K, Takeyama H, Sherman ML, Spriggs DR, Carney WP, Kufe DW. Effects of tiazofurin on globin and protooncogene expression in K562 erythroleukemia cells. **Cancer Communications** 1989;1:191-197.
8. Nakamura T, Kharbanda S, Spriggs DR, Kufe DW. Effects of dexamethasone on induction of monocytic differentiation in human U937 cells by dimethyl sulphoxide. **J Cell Physiol** 1990;142:261-267.
9. Kharbanda S, Band V, Murugesan K, Farooq A. Modulation of steroid production in goat ovarian cells: Effect of synthetic progestins and antiprogestins. **Endocrine Research** 1990;16:293-309.

10. Kharbanda S, Sherman ML, Kufe DW. Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells. **Blood** 1990;75:583-588.
11. Kharbanda S, Nakamura T, Datta R, Sherman ML, Kufe DW. Induction of monocytic differentiation by TNF in phorbol ester resistant Ka-1a cells. **Cancer Communications** 1990;2:327-332.
12. Kharbanda S, Sherman ML, Kufe DW. Transcriptional regulation of c-jun gene expression by 1- β -D-arabinofuranosylcytosine in human myeloid leukemia cells. **J Clin Invest** 1990;86:1517-1523.
13. Kharbanda S, Datta R, Kufe DW. Regulation of c-fos gene expression by 1- β -D-arabinofuranosylcytosine in human KG-1 myeloid cells. **Cancer Communications** 1990;2:409-414.
14. Datta R, Kharbanda S, Kufe DW. Regulation of jun B gene expression by 1- β -D-arabinofuranosylcytosine in human myeloid leukemia cells. **Molecular Pharmacology** 1990; 38:435-439.
15. Dhawan RK, Kharbanda S, Nakamura M, Ohno T, Kufe DW. Effects of granulocyte-macrophage colony-stimulating factor on 3'-azido-3'-deoxythymidine uptake, phosphorylation and nucleotide retention in human U-937 cells. **Biochemical Pharmacology** 1990;40:2695-2700.
16. Sherman ML, Stone RM, Datta R, Kharbanda S, Bernstein SB, Kufe DW. Regulation of c-jun gene expression by phorbol ester and tumor necrosis factor. In: Oppenheim JJ, Powanda MC, Kluger MJ, Dinarello CA, editors. **Molecular and Cellular Biology of cytokines**. New York: Wiley-Liss, Inc.; 1990. p 221-6.
17. Gunji H, Kharbanda S, Kufe DW. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1- β -D-arabinofuranosylcytosine. **Cancer Research** 1991, 51:3-7.
18. Pantazis T, Kharbanda S, Goustin AS, Galanopoulos T, Kufe DW. Coexpression of the genes for platelet derived growth factor β -chain receptor and macrophage colony stimulating factor 1

receptor during monocytic differentiation. **Proc Natl Acad Sci (USA)** 1991, 88:2481-2485.

19. Kharbanda S, Nakamura T, Stone R, Hass R, Bernstein SB, Datta R, Sukhatme VP, Kufe DW. Expression of the EGR-1 and EGR-2 zinc finger genes during induction of monocytic differentiation. **J Clin Invest** 1991, 88:571-577.
20. Rubin E, Kharbanda S, Gunji H, Kufe DW. Activation of the c-jun proto-oncogene in human myeloid leukemia cells treated with etoposide. **Molecular Pharmacology** 1991, 39:697-701.
21. Nakamura T, Datta R, Kharbanda S, Kufe DW. Regulation of jun and fos gene expression in human monocytes by the macrophage colony stimulating factor. **Cell Growth & Differentiation** 1991, 2:267-272.
22. Bernstein SB, Kharbanda S, Sherman ML, Sukhatme VP, Kufe DW. Posttranscriptional regulation of the zinc finger encoding EGR-1 gene by GM-CSF in human U-937 monocytic leukemia cells: Involvement of a pertussis toxin sensitive G protein. **Cell Growth & Differentiation** 1991, 2:273-278.
23. Bernstein SB, Sherman ML, Nakamura T, Hass R, Kharbanda S, Kufe DW. Effects of hexamethylene bisacetamide on induction of monocytic differentiation of human U-937 myeloid leukemia cells. **Biochemical Pharmacology** 1991, 42:403-407.
24. Bernstein SB, Kharbanda S, Sherman ML, Stone RM, Kufe DW. Inhibition of protein kinase-C is associated with a decrease in c-myc expression in human myeloid leukemia cells. **FEBS Letters** 1991, 294:73-76.
25. Kharbanda S, Datta R, Kufe DW. Regulation of c-jun gene expression in HL-60 leukemia cells by 1- β -D-arabinofuranosylcytosine. Involvement of a protein kinase C-dependent mechanism. **Biochemistry** 1991, 30:7947-7952.
26. Hass R, Brach M, Kharbanda S, Giese G, Traub P, Kufe DW. Inhibition of phorbol ester induced monocytic differentiation by dexamethasone is associated with down-regulation of fos and jun (AP-1). **J Cell Physiol** 1991, 149:125-131.

27. Hass R, Pfannkuche H-J, Kharbanda S, Gunji H, Meyer G, Hartmann A, Hidaka H, Resch K, Kufe D, Goppelt-Strübe M. Protein kinase C activation and proto-oncogene expression in differentiation/retrodifferentiation of human U-937 leukemia cells. **Cell Growth & Differentiation** 1991, 2:541-548.
28. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P, Kufe D. Camptothecin and its derivatives induce expression of the c-jun proto-oncogene in human myeloid leukemia cells. **Cancer Research** 1991, 51:6636-6142.
29. Datta R, Kharbanda S, Kufe D. Transcriptional and posttranscriptional regulation of H1 gene expression by 1- β -D-arabinofuranosylcytosine. **Molecular Pharmacology** 1992;41:64-68.
30. Brach M, Kharbanda S, Hartmann F, Kufe DW. Activation of the nuclear transcription factor kappa b in human myeloid leukemia cells treated with 1- β -D-arabinofuranosylcytosine. **Molecular Pharmacology** 1992, 41:60-63.
31. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D. Cisdiamminedichloroplatinum (II) induces c-jun expression in human leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. **Cancer Research** 1992, 52:878-882.
32. Kharbanda S, Datta R, Rubin E, Nakamura T, Hass R, Kufe DW. Regulation of c-jun expression during induction of monocytic differentiation by okadaic acid. **Cell Growth & Differentiation** 1992, 3:391-399.
33. Hass R, Gunji H, Datta R, Kharbanda S, Hartmann A, Weichselbaum R, Kufe DW. Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle regulatory genes. **Cancer Research** 1992, 52:1445-1450.
34. Datta R, Hallahan DE, Kharbanda S, Rubin E, Sherman ML, Huberman E, Weichselbaum RR, Kufe DW. Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. **Biochemistry** 1992, 31:8300-8306.

35. Nakamura T, Lin L, Kharbanda S, Knopf P, Kufe DW. Macrophage- colony stimulating factor activates phosphatidylcholine hydrolysis by cytoplasmic phospholipase A2. **EMBO J** 1992, 11:4917-4922.
36. Hass R, Brach M, Gunji H, Kharbanda S, Kufe DW. Dexamethasone inhibits expression of the EGR-1 and NF-kappa B early response gene during phorbol ester-induced human monocytic differentiation. **Biochemical Pharmacology** 1992, 44:1569-1576.
37. Kharbanda S, Rubin E, Datta R, Hass R, Sukhatme V, Kufe DW. Transcriptional regulation of the early growth response-1 gene in human myeloid leukemia cells by okadaic acid. **Cell Growth & Differentiation** 1993, 4:417-423
38. Kharbanda S, Nakamura T, Kufe DW. Induction of the c-jun proto-oncogene by a protein kinase C-dependent mechanism during exposure of human epidermal keratinocytes to ethanol. **Biochemical Pharmacology** 1993, 45:675-681.
39. Chauhan D, Kharbanda S, Rubin E, Barut BA, Mohrbacher A, Kufe DW, Anderson K. Regulation of c-jun gene expression in human T lymphocytes. **Blood** 1993, 81:1540-1548.
40. Hsu HC, Yang K, Kharbanda S, Clinton S, Datta R, Stone RM. All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells. **Leukemia** 1993, 7:458-462.
41. Slapak CA, Kharbanda S, Saleem A, Kufe DW. Defective translocation of protein kinase- C in multidrug resistant HL-60 cells confers a reversible loss of phorbol ester-induced monocytic differentiation. **J Biological Chemistry** 1993, 268: 12267-12273.
42. Kharbanda S, Huberman E, Kufe DW. Activation of the jun-D gene during treatment of human myeloid leukemia cells with 1- β -D-arabinofuranosylcytosine. **Biochemical Pharmacology** 1993, 45:2055-2061.
43. Hass R, Hirano M, Kharbanda S, Rubin E, Meinhardt G, Kufe DW. Resistance to phorbol ester-induced differentiation of a U-937 myeloid leukemia cell variant with a signaling defect

upstream to c-Raf-1 kinase. **Cell Growth & Differentiation** 1993, 657-663.

44. Kharbanda S, Saleem A, Rubin E, Sukhatme V, Blenis J, Kufe D. Activation of the early growth response-1 gene and nuclear pp90rsk in myeloid leukemia cells by 1- β -D-arabinofuranosylcytosine. **Biochemistry** 1993, 32:9137-9142.
45. Yang K, Tokihide M, Kharbanda S, Datta R, Huberman E, Kufe DW, Stone RM. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. **Blood** 1994, 83:490-496.
46. Chauhan D, Kharbanda S, Uchiyama H, Sukhatme V, Kufe DW, Anderson KC. Involvement of serum response element in okadaic acid induced EGR-1 gene expression in human T cells. **Cancer Research** 1994, 54:2234-2239.
47. Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U, Kufe DW. Activation of c-Raf-1 and mitogen activated protein kinases during induction of monocytic differentiation of human myeloid leukemia cells. **J Biological Chemistry** 1994, 269:872-878.
48. Kharbanda S, Saleem A, Emoto Y, Hirano M, Blenis J, Kufe DW. Activation of pp90rsk kinase during induction of monocytic differentiation in human myeloid leukemia cells. **Cell Growth & Differentiation** 1994, 5:259-265.
49. Kharbanda S, Saleem A, Datta R, Yuan Z-M, Weichselbaum R, Kufe D. Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2. **Cancer Research** 1994;54:1412-1414.
50. Kharbanda S, Emoto Y, Kisaki H, Saleem A, Kufe DW. 1- β -D-arabinofurano-sylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester resistant myeloid leukemia cells. **Molecular Pharmacology** 1994, 46:67-72.
51. Kharbanda S, Saleem A, Shafman T, Emoto Y, Weichselbaum R, Kufe DW. Activation of pp90rsk and mitogen activated protein kinase by ionizing radiation in human myeloid leukemia cells. **Proc Natl Acad Sci (USA)** 1994, 91:5416-5420.

52. Kharbanda S, Yuan Z-M, Taneja N, Kufe DW. p56/p53lyn activation in human myeloid cells treated with mitomycin C. **Oncogene** 1994, 9:3005-3011.
53. Kharbanda S, Yuan Z-M, Rubin E, Weichselbaum R, Kufe DW. Activation of Src-like protein tyrosine kinase Lyn by ionizing radiation. **J Biological Chemistry** 1994, 269:20739-20743.
54. Chauhan D, Kharbanda S, Uchiyama H, Kufe DW, Anderson KC. Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen. **Blood** 1994, 84:2243-2252.
55. Yuan Z-M, Kharbanda S, Kufe DW. 1- β -D-arabinofuranosylcytosine activate Src-like protein tyrosine kinase Lyn in human myeloid leukemia cells. **Biochemistry** 1995, 34:1058-1063.
56. Chauhan D, Kharbanda S, Kufe DW, Anderson K. Activation of pp90rsk and EGR-1 gene expression by pokeweed mitogen in human B cells. **Leukemia Research** 1995, 19:337-344.
57. Saleem A, Yuan Z-M, Taneja N, Rubin E, Kufe DW, Kharbanda S. Activation of serine/threonine protein kinases and early growth response-1 gene expression by tumor necrosis factor in human myeloid leukemia cells. **J Immunology** 1995, 154:4150-4156.
58. Kharbanda S, Saleem A, Yuan ZM, Emoto Y, Prasad KVS, Kufe D. Stimulation of human monocytes with M-CSF induces interaction of the GRB2 adaptor protein and the focal adhesion kinase, pp125^{FAK}. **Proc Natl Acad Sci (USA)** 1995, 92:6132-6136.
59. Saleem A, Kharbanda S *,Yuan Z-M, Kufe DW. M-CSF stimulates binding of phosphatidylinositol-3-OH kinase to Grb2/Sos complexes in human monocytes. **J Biological Chemistry** 1995, 270:10380-10383. * Communicating author.
60. Shafman T, Saleem A, Kyriakis J, Weichselbaum R, Kharbanda S, Kufe DW. Activation of stress activated protein kinase by ionizing radiation is defective in ataxia telangectasia. **Cancer Research** 1995, 55:3242-3245.

61. Kharbanda S *, Saleem A, Shafman T, Emoto Y, Taneja, N., Rubin E, Weichselbaum R, Woodgett J, Avruch J, Kyriakis J, Kufe D. Stimulation of the stress-activated protein kinase by ionizing radiation is negatively regulated through a Grb2-mediated association with phosphatidylinositol-3 kinase. **J Biological Chemistry** 1995, 270:18871-18874. * Communicating author.
62. Pandey P, Kharbanda S, Kufe DW. Association of the DF3/MUC1 breast cancer associated antigen with Grb2 and Sos, the Ras exchange protein. **Cancer Research** 1995, 55:4008-4013.
63. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller S, Weichselbaum R, Kufe DW. Activation of the c-Abl protein tyrosine kinase in the stress response to DNA-damaging agents. **Nature** 1995, 376:785-788.
64. Chauhan D, Kharbanda S, Ogata Y, Urishima M, Frank D, Mallik N, Kufe DW, Anderson K. Oncostatin-M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. **J Experimental Medicine** 1995, 182:1801-1806.
65. Emoto E, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, Kufe DW. Proteolytic activation of protein kinase Cd by an ice-like protease in apoptotic cells is inhibition by Bcl-2 and Bcl-x. **EMBO J** 1995, 14:6148-6156.
66. Kharbanda S *, Pandey P, Ren R, Mayer B, Zon L, Kufe DW. The c-Abl tyrosine kinase is activated by 1- β -D-arabinofuranosylcytosine. **J. Biological Chemistry** 1995, 270:30278-30281.* Communicating author
67. Saleem A, Datta R, Yuan Z-M, Pandey P, Kharbanda S, Kufe D. Involvement of stress activated protein kinase in the cellular response to 1- β -D-arabinofuranosylcytosine and other DNA damaging agents. **Cell Growth & Differentiation** 1995, 6:1651-1658.
68. Weichselbaum RR, Wayne JD, Mauceri HJ, Seung LP, Hanna NN, Kharbanda S, Hallahan DE, Kufe DW. Ionizing radiation: A molecular switch for gene therapy. In: **Gene therapy of cancer** 1995.

69. Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D. Activation of protein kinase Cd in human myeloid leukemia cells treated with 1- β -D-arabinofuranosylcytosine. **Blood** 1996, 87:1990-1906.
70. Kharbanda S, Bharti A, Wang J, Pandey P, Pei D, Ren R, Walsh C, Kufe D. The stress response to ionizing radiation involves c-Abl dependent phosphorylation of SHPTP-1. **Proc Natl Acad Sci (USA)** 1996, 93:6898-6901.
71. Yuan Z, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D. c-Abl stimulates the transactivation function of p53 and G1 arrest by a DNA damage-dependent mechanism. **Nature** 1996, 382:272-275.
72. Kharbanda S, Saleem A, Yuan Z-M, Kraeft S, Weichselbaum R, Chen LB, Kufe DW. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/53lyn tyrosine kinase with p34cdc2. **Cancer Research** 1996, 56:3617-3621.
73. Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis R, Kufe D, Kharbanda S. Activation of p38 MAPK by c-Abl-dependent and -independent pathways. **J Biological Chemistry** 1996, 271:23775-23779.
74. Yuan Z-M, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe DW. Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1- β -D-arabinofuranosylcytosine. **Oncogene** 1996, 13:939-946.
75. Yuan Z-M, Huang Y, Fan M, Sawyers C, Kharbanda S, Kufe D. Association of c-Abl protein tyrosine kinase with p53 in response to genotoxic drugs. **J Biological Chemistry** 1996, 271:26457-26460.
76. Ghayur T, Hugunin M, Talanian R, Ratnofsky S, Quinlan, C, Emoto Y, Pandey P, Datta R, Kharbanda S, Allen H, Kamen R, Wong W, Kufe D. Proteolytic activation of protein kinase C-delta by an ICE/CED 3-like protease induces characteristics of apoptosis. **J Experimental Medicine** 1996, 184:2399-2404.

77. Chauhan D, Kharbanda S, Ogata A, Kufe DW, Anderson K. Induction of SAP/JNK kinase and apoptosis by anti-Fas in multiple myeloma cells. **Blood** 1997, 89: 227-234.
78. Yuan Z-M, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl protein tyrosine kinase. **Proc Natl Acad Sci (USA)** 1997, 94:1437-1440.
79. Kharbanda S, Pandey P, Jin S, Satoshi I, Bharti A, Yuan Z-M, Weichselbaum R, Weaver D, Kufe D. Functional interactions of the DNA-dependent protein kinase and the c-Abl protein tyrosine kinase in the response to DNA damage. **Nature** 1997, 386:732-735.
80. Shafman T, Khanna KK, Kedar P, Yen T, Spring K, Kozlov S, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, Lavin MF. Role of ATM protein in stress response to DNA damage: evidence for interaction with c-Abl. **Nature** 1997, 387:520-3.
81. Kharbanda S, Pandey P, Schofield L, Roncinske R, Israel S, Bharti A, Yuan Z-M, Weichselbaum R, Saxena S, Nalin C, Kufe D. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in apoptosis. **Proc Natl Acad Sci (USA)** 1997, 94:6939-6942.
82. Chauhan D, Kharbanda S, Pandey P, Ogata A, Anderson K. Differential activation of SAP/JNK during induction of apoptosis. **Oncogene** 1997, 15:837-843.
83. Huang Y, Yuan Z-M, Ishiko T, Nakada S, Utsugisawa T, Kato T, Kharbanda S, Kufe DW. Pro-apoptotic effect of the c-Abl protein tyrosine kinase in the cellular response to 1- β -D-arabinofuranosylcytosine. **Oncogene** 1997, 15:1947-1952.
84. Yuan Z-M, Utsugisawa T, Huang Y, Ishiko T, Nakada S, Kharbanda S, Weichselbaum R, Kufe D. Inhibition of Phosphoinositol-3 kinase by c-Abl in the genotoxic stress response. **J Biological Chemistry** 1997, 272:23485-23488.
85. Jin S, Kharbanda S, Meyer B, Kufe D, Weaver D. DNA-dependent protein kinase catalytic subunit: Binding of the Ku activator

- and c-Abl tyrosine kinase. **J Biological Chemistry** 1997, 272:24763-24766.
86. Chauhan D, Pandey P, Ogata A, Kufe D, Kharbanda S, Anderson KA. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells. **J Biological Chemistry** 1997, 272:29995-29997.
87. Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D. Functional role for the c-Abl protein kinase in the cellular response to genotoxic stress. **Biochimica et Biophysica Acta** 1997, 1333:1-7.
88. Kha B, Kharbanda S, Narula J. Apoptosis in cardiovascular system. **Chest** 1997, 112:1358-62.
89. Yuan Z-M, Huang, Y, Ishiko T, Shinohara S, Kharbanda S, Sung P, Weichselbaum R, Kufe D. Functional interactions of RAD51 with c-Abl in response to DNA damage. **J Biological Chemistry** 1998, 273:3799-3802.
90. Yuan Z-M, Huang YY, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Functional interactions of c-Abl and protein kinase Cd in response to DNA damage. **Oncogene** 1998, 16:1643-1648.
91. Kharbanda S *, Pandey P, Morris, P, Xu Y, Whang Y, Zhu L-J, Kumar N, Yuan Z-M, Saywers C, Weichselbaum R, Pandita T, Kufe D. Functional role of c-Abl tyrosine kinase in meiosis I. **Oncogene** 1998, 16:1773-1778. * Communicating author.
92. Kumar S, Pandey P, Bharti A, Jin S, Weichselbaum R, Weaver D, Kufe D and Kharbanda S. Regulation of DNA-dependent protein kinase by the Lyn tyrosine kinase. **J Biological Chemistry** 1998, 273:25654-25658.
93. Liedtke M, Pandey P, Kumar S, Sawyers C, Kharbanda S and Kufe D. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by SHPTP1 protein tyrosine phosphatase. **Oncogene** 1998, 17:1889-1892.
94. Bharti A, Kraeft S, Gounder M, Pandey P, Jin S, Yuan YM, Lees-Miller S, Weichselbaum R, Weaver D, Chen LB, Kufe D and Kharbanda S. Inactivation of DNA-dependent protein kinase by

- protein kinase C δ : Implications for apoptosis. **Molecular and Cellular Biology** 1998, 18:6719-6728.
95. Yuan YM, Kharbanda S, Weichselbaum R, Kufe D. Involvement of the c-Abl tyrosine kinase in the apoptotic response to anti-cancer agents. In: Hickman J and Dive C, eds. **Cancer Chemotherapy and Apoptosis**. Humana Press. 1998.
 96. Kharbanda S, Yuan Y, Weichselbaum R and Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. **Oncogene** 1998, 17:3309-3318.
 97. Kaneki M, Kharbanda S, Pandey P, Liou JR, Stone R, Kufe D. Functional role for protein kinase C- β as a regulator of phorbol ester-induced SAPK/JNK activity in monocytic differentiation of myeloid leukemia cells. **Molecular and Cellular Biology** 1999, 19:461-470.
 98. Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S, Yoshida K, Talanian R, Weichselbaum R, Kufe D and Yuan ZM. Essential role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. **Molecular and Cellular Biology** 1999, 19:2986-2997.
 99. Pandey P, Avraham S, Place A, Kumar V, Majumdar P, Chang K, Nakazawa A, Saxena S and Kharbanda S. Bcl-xL blocks activation of RAFTK/PYK2 and SAPK/JNK in the cellular response to methylmethane sulphonate. **J Biological Chemistry** 1999, 274:8618-8623.
 100. Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, Rana A, Avraham H, Davis R and Kharbanda S. Activation of p38 MAP kinase by PYK2/RAFTK-dependent mechanism. **J Biological Chemistry** 1999, 274:10140-10145.
 101. Narula J, Pandey P, Arbustini E, Haider N, Kolodgie F, Israels S, Semigran M, William Dec G, Virmani R, Saxena S, Kharbanda S. Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. **Proc Natl Acad Sci (USA)** 1999, 96:8144-8149.
 102. Yuan Y, Sun P, Kharbanda S, Weichselbaum R and Kufe D. Role for p73 and c-Abl in apoptosis in response to DNA damage. **Nature** 1999 399:814-817.

103. Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S and Anderson K. Protein tyrosine kinase RAFTK mediate dexamethasone-induced apoptosis in multiple myeloma cells. **Oncogene** 1999, 18:6733-6740.
104. Kumar S, Avraham S, Bharti A, Pandey P and Kharbanda S. Negative regulation of PYK2/RAFTK signal transduction by hematopoietic tyrosine phosphatase SHPTP1. **J Biological Chemistry** 1999, 274: 30657-30663.
105. Yoshida K, Kharbanda S and Kufe D. Phosphorylation of SHPTP1 by the Lyn tyrosine kinase in response to DNA damage. **J Biological Chemistry** 1999, 274:34663-34668.
106. Kharbanda S, Saxena S, Yoshida K, Pandey P, Wang O, Cheng K, Cheng YN, Campbell A, Thangrila S, Narula J, Yuan ZM, Weichselbaum R, Nalin C and Kufe D. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. **J Biological Chemistry** 2000, 275:322-327.
107. Chimura S, Nodzenski, E., Kharbanda, S., Pandey, P., Quintans, J., Kufe D., and Weichselbaum R. Downregulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. **Molecular Pharmacology** 2000, 57:792-796.
108. Pandey P, Farber R, Kumar S, Bharti A, Nalin C, Kufe D, and Kharbanda S. Hsp27 functions as a negative regulator of cytochrome C-dependent activation of caspase-3. **Oncogene** 2000, 19:1975-1981.
109. Sun, X., Wu F., Datta, R., Kharbanda S and Kufe D. Interaction between protein kinase C δ and the c-Abl tyrosine kinase in the cellular response to oxidative stress. **J Biological Chemistry** 2000, 275:7470-7473.
110. Kumar V, Pandey P, Sabatini D, Kumar M, Majumdar P, Carmichael G, Kufe D and Kharbanda S. Functional interaction between mammalian target of rapamycin and protein kinase C delta in the regulation of cap-dependent initiation of protein translation. **EMBO J** 2000, 19:1087-1097.

111. Kumar V, Pandey P, Gingras A, Sabatini D, Kumar M, Majumder P, Carmichael G, Sonenberg N, Kufe D and Kharbanda S. Functional interaction between RAFT1/mTOR and c-Abl in the regulation of CAP-dependent initiation of translation. **J Biological Chemistry** 2000, 275:10779-10787.
112. Kharbanda S., Kumar V., Sawant S., Pandey P., Chen C., Counter C., Smilenov L., Yuan Z., Whang Y., Sawyers C., Strauss W., Pandita T., Weaver D., and Kufe D. Regulation of the hTERT telomerase subunit by the c-Abl protein tyrosine kinase. **Current Biology** 2000, 10:568-575.
113. Ito Y, Pandey P, Place A., Sporn M.B., Gribble G, Honda T, Kharbanda S and Kufe D. The novel triterpenoid CDDO induces apoptosis of human myeloid leukemia cells by a caspase-8 dependent mechanism. **Cell Growth & Differentiation** 2000, 11:261-267.
114. Kharbanda S *, Pandey P, Yamauchi T, Kaneki M, Kumar S, Kumar V, Bharti A, Yuan Y, Ghanem L., Rana A, Weichselbaum R, Johnson G, and Kufe D. Activation of MEKK-1 by c-Abl protein tyrosine kinase in response to DNA damage. **Molecular and Cellular Biology** 2000, 20:4979-4989. * Communicating author.
115. Sun, X., Majumder, P., Shioya, H., Wu, F., Kharbanda S., and Kufe, D. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. **J Biological Chemistry** 2000 275:17237-17240.
116. Yoshida K., Weichselbaum R., Kharbanda S., and Kufe D. Role for the Lyn tyrosine kinase as a regulator of SAPK/JNK kinase activity in response to DNA damage. **Molecular and Cellular Biology** 2000, 20:5370-5380.
117. Majumder, P, Pandey, P., Sun X, Cheng K, Datta R, Saxena, S., Kharbanda S., and Kufe, D. Mitochondrial translocation of protein kinase C δ in phorbol ester-induced cytochrome c release and apoptosis. **J Biological Chemistry** 2000, 275:21793-21796.
118. Pandey P, Nakazawa A, Ito Y, Datta R, Kharbanda S, and Kufe D. Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells. **Oncogene** 2000, 19: 3941-3947.

119. Pandey P, Nakazawa A, Kumar S, Nalin C, Weichselbaum R, Kufe D and Kharbanda S. Heat shock protein 90 beta negatively regulates Apaf-1-mediated cytochrome c-dependent activation of caspase-3. **EMBO J** 2000, 19:4310-4323.
120. Chauhan D, Pandey P, Hideshima T, Treon S, Tai-Y, Davies F, Raje N, Rosen S, Avraham S, Kharbanda S and Anderson K. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. **J Biological Chemistry** 2000, 275:27845-27850.
121. Ito Y, Pandey P, Place A, Sporn M, Datta R, Kharbanda S and Kufe D. The novel triterpinoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. **Molecular Pharmacology** 2001, 59:1094-1099.
122. Ito Y, Pandey P, Haider N, Rana A, Weichselbaum R, Tan T, Kufe D and Kharbanda S. Interaction of hematopoietic kinase 1 (HPK1) and the c-Abl protein tyrosine kinase in response to genotoxic stress. **J Biological Chemistry** 2001, 276:18130-18138.
123. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandramuri B, Kharbanda S and Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane derived tumstatin. **J Biological Chemistry** 2001, 276:15240-15248.
124. Cao C, Ren X, Kharbanda S, Koleske A, Prasad KVS and Kufe D. c-Abl-related ARG interacts with SIVA in the apoptotic response to oxidative stress. **J Biological Chemistry** 2001, 276:11465-11468.
125. Ito Y, Misra N, Saxena S, Kharbanda S and Kufe D. Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid leukemia cells. **Cell Death & Differentiation** 2001, 8:794-800.
126. Kumar S, Bharti A, Misra N, Kharbanda S, Saxena S and Kufe D. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. **J Biological Chemistry** 2001, 276:17281-17285.

127. Chauhan D, Hideshima T, Rosen S, Reed J, Kharbanda S and Anderson K. Apaf-1/cytochrome c independent and Smac-dependent induction of apoptosis in multiple myeloma cells. **J Biological Chemistry** 2001, 276:24453-24456.
128. Ito Y, Misra N, Pandey P, Narula N, Kharbanda S, Saxena S and Kufe D. Targeting of the c-Abl tyrosine kinase to mitochondria in ER stress-induced apoptosis. **Molecular and Cellular Biology** 2001, 21:6233-6242.
129. Majumder P, Misra N, Kharbanda S, Saxena S and Kufe D. Mitochondrial translocation of PKC delta in response to hydrogen peroxide. **Cell Growth & Differentiation** 2001, 12:465-470.
130. Maeshima Y, Yerramalla UL, Dhanbal M, Holthaus KA, Kharbanda S, Barbashov S, Reimer C, Manfredi M, Dickerson WM and Kalluri R. Extracellular matrix derived peptide binds to alpha v beta 3 integrin and inhibits angiogenesis. **J Biological Chemistry** 2001, 276:31959-31968.
131. Yin L, Ohno T, Weichselbaum R, Kharbanda S and Kufe D. The novel isocoumarin NM-3 induces lethality of human carcinoma cells by generation of reactive oxygen species. **Molecular Cancer Therapeutics** 2001, 1:41-45.
132. Narula J, Kharbanda S and Sluyser M. Apoptosis in the eyes of a clinician. **Apoptosis** 6(1,2): 5-6, 2001.
133. Maeshima Y, Sudhakar A, Lively J, Ueki K, Kharbanda S, Kahn R, Sonenberg N, Hynes R and Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. **Science**, 2002, 295:140-143.
134. Reimer C, Agata N, Tammam J, Bamberg M, Dickerson M, Kamphaus G, Rook S, Fram R, Kalluri R, Kufe D and Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. **Cancer Research**. 2002, 62: 789-795.
135. Raina D, Misra N, Kumar S, Kharbanda S, Saxena S and Kufe D. Inhibition of c-Abl with STI571 blocks SAPK activation and apoptosis in the cellular response to 1- β -D-

- arabinofuranosylcytosine. **Molecular Pharmacol.** 2002, 61: 1489-1495.
136. Ren X, Cao C, Zhu L, Yoshida K, Weichselbaum R, Kharbanda S and Kufe D. Lyn tyrosine regulates the p53 tumor suppressor by inhibiting nuclear export of the p53-Mdm2 complex. **Cancer Biology Therapeutics** 2002, 1: 703-708.
137. Kumar S, Misra N, Raina D, Kharbanda S, Saxena S and Kufe D. Abrogation of the apoptotic response to oxidative stress by the c-Abl tyrosine kinase inhibitor STS571. **Molecular Pharmacol.** 2003, 63: 276-282.
138. Chauhan D, Li G, Hideshima T, Podar K, Munshi N, Kharbanda S and Anderson K. JNK-dependent release of mitochondrial protein, Smac during apoptosis in multiple myeloma (MM) cells. **J. Biological Chemistry.** 2003, 278: 17593-17596.
139. Li Y, Liu D, Chen D, Kharbanda S and Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. **Oncogene.** 2003, 22: 6107-6110.
140. Li Y, Yu W-H, Ren J, Huang L, Kharbanda S, M Loda and Kufe D. Heregulin targets β -catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. **Molecular Cancer Research.** 2003, 1: 765-775.
141. Huang L, Ren J, Chen D, Li Y, Kharbanda S and Kufe D. Human MUC1 cytoplasmic domain co-activates Wnt target gene transcription and confers transformation. **Cancer Biology & Therapeutics.** 2003, 2(6): 702-706.
142. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L, Raina D, Chen W, Kharbanda S and Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. **Cancer Cell,** 2004, 5: 163-175.
143. Raina D, Kharbanda S and Kufe D. The DF3/MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways. **J. Biological Chemistry,** 2004, 279: 20607-20612.
144. Agata N, Nogi H, Milhollen M, Kharbanda S and Kufe D. NM-3, a small molecule isocoumarin, potentiates dexamethasone-induced

- apoptosis of human multiple myeloma cells. **Cancer Research**, 2004, 64:8512-8516.
145. Yu D, Khan E, Laco G, Kohlhagen G, Kharbanda S, Cheng Y-C, Pommier Y and Bharti A. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. **J. Biological Chemistry**, 2004, 279: 51851-51861.
146. Agata N, Nogi H, Bamberg M, Weitman S, Kharbanda S and Kufe D. The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. **Cancer Chemotherapy and Pharmacology**. 2005, 56:610-614.
147. Raina D, Pandey P, Ahmed R, Bharti A, Kharbanda S, Weichselbaum R and Kufe D. c-Abl tyrosine kinase regulates caspase-9 activation in the apoptotic response to DNA damage. **J. Biological Chemistry**. 2005, 280: 11147-11151.
148. Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D. MUC1 oncoprotein blocks GSK3 β -mediated phosphorylation and degradation of b-catenin. **Cancer Research**. 2005, 65 (22): 10413-10422
149. Duraisamy S, Ramasamy S, Kharbanda S and Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16. **Gene**. 2006, 373: 28-34.
150. Raina D, Rehan A, Jian Ren, Yoshida K, Kharbanda S and Kufe D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. 2006, **EMBO J**. 25(16): 3774-3783.
151. Kwano T, Agata A, Kharbanda S, Avigan D and Kufe D. A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. **Cancer Chemotherapy and Pharmacology**, 2007, 59: 329-335
152. Ahmad R, Raina D, Meyer, C, Kharbanda S and Kufe D. Triterpenoid CDDO-Me blocks the NF-kB pathway by direct inhibition of the IKK β on Cys-179 **J. Biological Chemistry**, 2007, 281: 35764-35769.

153. Yin L, Kharbanda S and Kufe D. MUC1 oncoprotein blocks HIF-1 α activation in a survival response to hypoxia. **J. Biological Chemistry**, 2007, 282:257-266.
154. Ramasamy S, Duraiswamy S, Barbashov S, Kawano T, Kharbanda S and Kufe D. The MUC1 and Galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. **Molecular Cell**. 27(6): 992-1004, 2007.
155. Ahmad R, Raina D, Trivedi V, Kharbanda S and Kufe D. MUC1 oncoprotein activates the I κ B kinase complex and constitutive NF- κ B signaling. Revised Submitted, **Nature Cell Biology**. 9(12): 1419-1427, 2007.
156. Agata N, Kawano T, Ahmad R, Raina D, Kharbanda S and Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by direct inhibition of caspase-8. **Cancer Research**, 68:6136-6144, 2008.
157. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S and Kufe D. The MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. **Cancer Biology and Therapeutics**, 7(12): 1959-1967, 2008.
158. Yin L, Kharbanda S and Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. **International Journal of Oncology**. 34: 1691-1699, 2009.
159. Raina D, Ahmad R, Chen D, Joshi M, Kharbanda S and Kufe D. Targeting of the MUC1 oncoprotein blocks tumorigenicity of human breast cancer cells. **Cancer Research**, 69: 5133-5141, 2009.
160. Ahmad R, Raina D, Joshi M, Kawano T, Ren J, Kharbanda S and Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF- κ B p65 transcription factor. **Cancer Research**, 69(17): 7013-7021, 2009.
161. Joshi MD, Ahmad R, Raina D, Yin L, Rajabi H, Bubley G, Kharbanda S and Kufe D. Addition to the MUC1 oncoprotein in human prostate cancer. **Molecular Cancer Therapeutics**, 8(11): 3056-3065, 2009.

162. Ahmed R, Liu S, Weisberg E, Nelson E, Meyer C, Kufe D, Kharbanda S and Stone R. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with ITD mutation. **Molecular Cancer Research**, 8(7): 986-993, 2010.
163. Huang L, Liao X, Beckett M, Li Y, Yi H, Khanna KK, Wang Z, Kharbanda S, Weichselbaum R and Kufe D. MUC1 oncoprotein interacts directly with ATM and promotes the DNA damage response to ionizing radiation. Submitted, **Genes & Cancer**. 1(3): 239-250, 2010.
164. Yin L, Ahmad R, Kosugi M, Kufe T, Vasir B, Avigan D, Kharbanda S and Kufe D. Survival of human multiple myeloma cells is dependent on MUC1-C oncoprotein function. **Molecular Pharmacology**. 78(2): 166-174, 2010.
165. Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, Kharbanda S and Kufe D. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. **Cancer Biol. Ther.** 10(5): 483-491, 2010.
166. Ahmad R, Raina D, Rajabi H, Joshi M, Kharbanda S and Kufe D. Expression of the MUC1 oncoprotein is activated by an auto-inductive STAT3-dependent regulatory loop. **Science Signaling**. 4 (160):1-14, 2011.
167. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Supko J, Kharbanda S and Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells with EGFR and K-Ras mutations. **Molecular Cancer Therapeutics**, 2011.
168. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S and Kufe D. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. **Blood**, 2011.
169. Xinping Y, Suiyang S, Kharbanda S and Stone R. AKT1 induces caspase-mediated cleavage of CDK inhibitor p27Kip1 in the progression of cell cycle in leukemia cells transformed by a FLT3 internal tandem duplication mutant. **Molecular Pharmacology**, Submitted, February, 2011.

170. Nelson E, Suiyang S, Kharbanda S, Stone R and Frank D.
Synergistic effects of FLT3-ITD and STAT5 inhibitors in the
regulation of AML. **In Preparation.**

Patents/Applications

1. U.S. Patent Application, "Methods and compositions including DNA damaging agents and tyrosine kinase inhibitors or activators," ARCD: 197. **Surender Kharbanda, Ralph Weischlebaum and Donald Kufe.** 1998.
2. U.S. Patent Application, "Relates to compounds and methods useful in regulating apoptosis". **Surender Kharbanda, Carlo Nalin and Donald Kufe.** 1998.
3. U.S. Patent application, "Relates to tumor chemopotential using isocoumarin derivatives". Application 2-23-2001. Granted [Date: 5-31-2005] United States Patent No.: US 6,900,239 B2. **Naoki Agata and Surender Kharbanda.**
4. U.S. Patent Application, "MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom". Application filed 5-29-2003. Publication Date 1-29-2004. Publication No.: US 20040018181 A1. **Donald Kufe, Surender Kharbanda and Steven Weitman.**
5. U.S. Patent Application, "MUC1 C-terminal tail phospho antibody: its uses in diagnosis" **Surender Kharbanda, Yongqing Li and Donald Kufe.** 2003.
6. U.S. Patent application. Modulation of MUC1 mediated signal transduction. **Albert A. Jecminek, Surender Kharbanda, Naoki Agata and Donald W. Kufe.** 2003.

7. U.S. Provisional patent application. "Matrilysin mediated modulation of MUC1 mediated signal transduction." Wei-Hsaun Yu, Yongqing Li, Surender Kharbanda and Donald Kufe. 2003.
8. U.S. Patent Application, provisional application for United States Letters patent for "Composition and Methods of use of MUC1-ligand traps". Surender Kharbanda and Donald Kufe. 2003.
9. U.S. Patent Application, 60/519,822; 60/514,198.
International Patent Application No. PCT/US2004/034680.
International Publication Number WO 2005/042573 A1.
"Modulation of the interaction of MUC1 with MUC1 ligands".
Surender Kharbanda and Donald Kufe. 2004
10. Provisional Application for United States Patent
[GENU:022USP1], "MUC1-Cytoplasmic Domain Peptides as
Inhibitors of Cancer". Surender Kharbanda and Donald Kufe.
Filed on October 27, 2008.
11. Provisional Application for United States Patent "MUC1-
Cytoplasmic Domain Peptides: their role as cytokine-induced
anti-Inflammatory agents". Surender Kharbanda and Donald
Kufe. 2009.
12. United States Patent Application, serial number 10/598,295.
MUC1 antagonist enhancement of death receptors ligand-induced
apoptosis. Surender Kharbanda and Donald Kufe. Filed April
5, 2007.

13. United States Provisional Application filed for letters of Patent. "Inhibition of Inflammation using antagonists of MUC1". **Donald Kufe and Surender Kharbanda**. Filed on Oct 16, 2009.
14. United States Provisional Patent Application filed for letters of Patent. "Small molecule inhibitors of MUC1 and methods of identifying the same". **Donald Kufe and Surender Kharbanda**. Provisional patent filed on March 15th, 2010.
15. Provisional Application for United States Patent "Improved antagonists of MUC1". **Surender Kharbanda and Donald Kufe**. Filed on February 11, 2011.